Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | MTTP | P55157 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5399096 | 0.94 | CYP1A2 (0.47) | LMNARAB9ANR1H4EPHX2HDAC6 | |
| SCHEMBL5402275 | 0.93 | HDAC1 (0.55) | LMNARAB9ANR1H4EPHX2HDAC6 | |
| SCHEMBL5402883 | 0.91 | NR1H4 (0.55) | LMNARAB9ANR1H4EPHX2HDAC6 | |
| SCHEMBL5392150 | 0.91 | ALDH1A1 (0.53) | LMNARAB9ANR1H4EPHX2 | |
| SCHEMBL5400848 | 0.90 | CHRNB2 (0.57) | LMNARAB9AHDAC6HDAC1CHRNB2 | |
| SCHEMBL5405971 | 0.90 | NR1H4 (0.54) | LMNARAB9ANR1H4EPHX2CHRNB2 | |
| SCHEMBL5409532 | 0.89 | HDAC1 (0.59) | HDAC6HDAC1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5398638 | 0.86 | KMT2A (0.54) | LMNARAB9AHDAC6HDAC1CHRNB2 | |
| SCHEMBL5399681 | 0.86 | KMT2A (0.54) | LMNARAB9AHDAC6HDAC1CHRNB2 | |
| SCHEMBL5401104 | 0.86 | ALDH1A1 (0.52) | LMNAHDAC6HDAC1CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | LMNA 308/4885RAB9A 3132/4885NR1H4 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.